Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.34 |
| ▸ | BRD4 | O60885 | 5/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30555493 | 1.00 | KDM4C (0.37) | KDM4CMAP3K5CREBBPBRD4SSTR4 | |
| SCHEMBL23248587 | 0.95 | KDM4C (0.34) | KDM4CMAP3K5CREBBPBRD4SSTR4 | |
| SCHEMBL30555471 | 0.93 | KDM4C (0.42) | KDM4CMAP3K5CREBBPBRD4SSTR4 | |
| SCHEMBL26123310 | 0.93 | KDM4C (0.42) | KDM4CMAP3K5CREBBPBRD4SSTR4 | |
| SCHEMBL23248586 | 0.89 | KDM4C (0.33) | KDM4C | |
| SCHEMBL30555505 | 0.88 | BRD4 (0.33) | CREBBPBRD4 | |
| SCHEMBL26121015 | 0.88 | BRD4 (0.33) | CREBBPBRD4 | |
| SCHEMBL30555443 | 0.87 | KDM4C (0.38) | KDM4CMAP3K5CREBBPBRD4SSTR4 | |
| SCHEMBL23248473 | 0.87 | KDM4C (0.38) | KDM4CMAP3K5CREBBPBRD4SSTR4 | |
| SCHEMBL23248559 | 0.84 | AXL (0.33) | KDM4CIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358879-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-15 | — | — | US | disclosed |
| EP-4046688-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| EP-4046688-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | PARK7, SMN1; SMN2, SNCA | KDM4C 1231/4885MAP3K5 1166/4885CREBBP 433/4885 |
| US-12358879-B2 | Heterocyclic compound | PARK7, SMN1; SMN2, SNCA | KDM4C 1231/4885MAP3K5 1166/4885CREBBP 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.